Table 2.
Outcomes for the Lymphoma SPORE Molecular Epidemiology Resource participants enrolled 2002 to 2012 and followed through mid-2016
| DLBCL (N = 1007) | FL (N = 905) | CLL/SLL (N = 1197) | MCL (N = 257) | MZL (N = 420) | Other B-cell lymphomas (N = 432) | Composite/ discordant (N = 253) | HL (N = 486) | TCL (N = 335) | Other NHL NOS (N = 153) | Total (N = 5445) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EFS status | |||||||||||
| No event | 535 (53.1%) | 435 (48.1%) | 742 (62.0%) | 86 (33.5%) | 256 (61.0%) | 219 (50.7%) | 130 (51.4%) | 369 (75.9%) | 126 (37.6%) | 57 (37.3%) | 2955 (54.3%) |
| Event | 472 (46.9%) | 470 (51.9%) | 455 (38.0%) | 171 (66.5%) | 164 (39.0%) | 213 (49.3%) | 123 (48.6%) | 117 (24.1%) | 209 (62.4%) | 96 (62.7%) | 2490 (45.7%) |
| Follow-up status | |||||||||||
| Alive | 635 (63.1%) | 741 (81.9%) | 884 (73.9%) | 131 (51.0%) | 352 (83.8%) | 287 (66.4%) | 180 (71.1%) | 419 (86.2%) | 175 (52.2%) | 67 (43.8%) | 3871 (71.1%) |
| Dead | 372 (36.9%) | 164 (18.1%) | 313 (26.1%) | 126 (49.0%) | 68 (16.2%) | 145 (33.6%) | 73 (28.9%) | 67 (13.8%) | 160 (47.8%) | 86 (56.2%) | 1574 (28.9%) |
| Lymphoma-specific survival status | |||||||||||
| No event | 769 (76.4%) | 826 (91.3%) | 1068 (89.2%) | 170 (66.1%) | 400 (95.2%) | 349 (80.8%) | 208 (82.2%) | 452 (93.0%) | 225 (67.2%) | 96 (62.7%) | 4563 (83.8%) |
| Event | 238 (23.6%) | 79 (8.7%) | 129 (10.8%) | 87 (33.9%) | 20 (4.8%) | 83 (19.2%) | 45 (17.8%) | 34 (7.0%) | 110 (32.8%) | 57 (37.3%) | 882 (16.2%) |
| Follow-up years (alive cases) | |||||||||||
| N | 635 | 741 | 884 | 131 | 352 | 287 | 180 | 419 | 175 | 67 | 3871 |
| Median | 6.1 | 6.9 | 6.9 | 5.9 | 6.0 | 5.9 | 6.1 | 5.6 | 5.2 | 5.6 | 6.1 |
| Range | (0.0–13.4) | (0.1–13.3) | (0.0–13.5) | (0.4–13.1) | (0.4–13.1) | (0.2–12.9) | (0.1–13.7) | (0.0–13.0) | (0.1–12.9) | (0.4–12.4) | (0.0–13.7) |
DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukaemia/small lymphocytic lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; HL, Hodgkin lymphoma; TCL, T-cell lymphoma; NHL, non-Hodgkin lymphoma; NOS, not otherwise specified.